These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21420850)

  • 1. Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy.
    Jung ST; Kang TH; Kelton W; Georgiou G
    Curr Opin Biotechnol; 2011 Dec; 22(6):858-67. PubMed ID: 21420850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aglycosylated full-length IgG antibodies: steps toward next-generation immunotherapeutics.
    Ju MS; Jung ST
    Curr Opin Biotechnol; 2014 Dec; 30():128-39. PubMed ID: 25035939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal combination of beneficial mutations for improved ADCC effector function of aglycosylated antibodies.
    Yoon HW; Jo M; Ko S; Kwon HS; Lim CS; Ko BJ; Lee JC; Jung ST
    Mol Immunol; 2019 Oct; 114():62-71. PubMed ID: 31336250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. With or without sugar? (A)glycosylation of therapeutic antibodies.
    Hristodorov D; Fischer R; Linden L
    Mol Biotechnol; 2013 Jul; 54(3):1056-68. PubMed ID: 23097175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering Aglycosylated IgG Variants with Wild-Type or Improved Binding Affinity to Human Fc Gamma RIIA and Fc Gamma RIIIAs.
    Chen TF; Sazinsky SL; Houde D; DiLillo DJ; Bird J; Li KK; Cheng GT; Qiu H; Engen JR; Ravetch JV; Wittrup KD
    J Mol Biol; 2017 Aug; 429(16):2528-2541. PubMed ID: 28694069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies.
    Kayser V; Chennamsetty N; Voynov V; Forrer K; Helk B; Trout BL
    Biotechnol J; 2011 Jan; 6(1):38-44. PubMed ID: 20949542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural consequences of aglycosylated IgG Fc variants evolved for FcγRI binding.
    Ju MS; Na JH; Yu YG; Kim JY; Jeong C; Jung ST
    Mol Immunol; 2015 Oct; 67(2 Pt B):350-6. PubMed ID: 26153451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aglycosylated antibodies and the methods of making and using them: WO2008030564.
    Jefferis R
    Expert Opin Ther Pat; 2009 Jan; 19(1):101-5. PubMed ID: 19441902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation and comparative characterization of glycosylated and aglycosylated human IgG1 antibodies.
    Hristodorov D; Fischer R; Joerissen H; Müller-Tiemann B; Apeler H; Linden L
    Mol Biotechnol; 2013 Mar; 53(3):326-35. PubMed ID: 22427250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aglycosylated antibody-producing mice for aglycosylated antibody-lectin coupled immunoassay for the quantification of tumor markers (ALIQUAT).
    Lee NE; Kim SH; Yu DY; Woo EJ; Kim MI; Seong GS; Lee SM; Ko JH; Kim YS
    Commun Biol; 2020 Oct; 3(1):636. PubMed ID: 33128033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Role of Carbohydrate Residues in Human Immunoglobulin G and Therapeutic Monoclonal Antibodies.
    Dorokhov YL; Sheshukova EV; Kosobokova EN; Shindyapina AV; Kosorukov VS; Komarova TV
    Biochemistry (Mosc); 2016 Aug; 81(8):835-57. PubMed ID: 27677552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
    Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
    PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcγRIIa affinity and selectivity.
    Jung ST; Kelton W; Kang TH; Ng DT; Andersen JT; Sandlie I; Sarkar CA; Georgiou G
    ACS Chem Biol; 2013 Feb; 8(2):368-75. PubMed ID: 23030766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region.
    Tao MH; Morrison SL
    J Immunol; 1989 Oct; 143(8):2595-601. PubMed ID: 2507634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epitope characterization of pre-existing and developing antibodies to an aglycosylated monoclonal antibody therapeutic of G1m17,1 allotype.
    Tatarewicz SM; Juan G; Swanson SJ; Moxness MS
    J Immunol Methods; 2012 Aug; 382(1-2):93-100. PubMed ID: 22609464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular analysis of IgM rheumatoid factor binding to chimeric IgG.
    Artandi SE; Canfield SM; Tao MH; Calame KL; Morrison SL; Bonagura VR
    J Immunol; 1991 Jan; 146(2):603-10. PubMed ID: 1702808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avidity confers FcγR binding and immune effector function to aglycosylated immunoglobulin G1.
    Nesspor TC; Raju TS; Chin CN; Vafa O; Brezski RJ
    J Mol Recognit; 2012 Mar; 25(3):147-54. PubMed ID: 22407978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterizing the effect of multiple Fc glycan attributes on the effector functions and FcγRIIIa receptor binding activity of an IgG1 antibody.
    Pace D; Lewis N; Wu T; Gillespie R; Leiske D; Velayudhan J; Rohrbach A; Connell-Crowley L
    Biotechnol Prog; 2016 Sep; 32(5):1181-1192. PubMed ID: 27160519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB.
    Stopforth RJ; Cleary KL; Cragg MS
    J Clin Immunol; 2016 May; 36 Suppl 1():88-94. PubMed ID: 26922075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgG Fc engineering to modulate antibody effector functions.
    Wang X; Mathieu M; Brezski RJ
    Protein Cell; 2018 Jan; 9(1):63-73. PubMed ID: 28986820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.